Novel Polymyxin Derivatives Carrying Only Three Positive Charges Are Effective Antibacterial Agents

Antimicrobial Agents and Chemotherapy
2008.0

Abstract

The lack of novel antibiotics against gram-negative bacteria has reinstated polymyxins as the drugs of last resort to treat serious infections caused by extremely multiresistant gram-negative organisms. However, polymyxins are nephrotoxic, and this feature may complicate therapy or even require its discontinuation. Like that of aminoglycosides, the nephrotoxicity of polymyxins might be related to the highly cationic nature of the molecule. Colistin and polymyxin B carry five positive charges. Here we show that novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. NAB739 has a cyclic peptide portion identical to that of polymyxin B, but in the linear portion of the peptide, it carries the threonyl-D-serinyl residue (no cationic charges) instead of the diaminobutyryl-threonyl-diaminobutyryl residue (two cationic charges). The MICs of NAB739 for 17 strains of Escherichia coli were identical, or very close, to those of polymyxin B. Furthermore, NAB739 was effective against other polymyxin-susceptible strains of Enterobacteriaceae and against Acinetobacter baumannii. At subinhibitory concentrations, it dramatically sensitized A. baumannii to low concentrations of antibiotics such as rifampin, clarithromycin, vancomycin, fusidic acid, and meropenem. NAB739 methanesulfonate was a prodrug analogous to colistin methanesulfonate. NAB740 was the most active derivative against Pseudomonas aeruginosa. NAB7061 (linear portion of the peptide, threonyl-aminobutyryl) lacked direct antibacterial activity but sensitized the targets to hydrophobic antibiotics by factors up to 2,000. The affinities of the NAB compounds for isolated rat kidney brush border membrane were significantly lower than that of polymyxin B.

Knowledge Graph

Similar Paper

Novel Polymyxin Derivatives Carrying Only Three Positive Charges Are Effective Antibacterial Agents
Antimicrobial Agents and Chemotherapy 2008.0
A Novel Polymyxin Derivative That Lacks the Fatty Acid Tail and Carries Only Three Positive Charges Has Strong Synergism with Agents Excluded by the Intact Outer Membrane
Antimicrobial Agents and Chemotherapy 2010.0
Activity and Predicted Nephrotoxicity of Synthetic Antibiotics Based on Polymyxin B
Journal of Medicinal Chemistry 2016.0
Discovery of Dap-3 Polymyxin Analogues for the Treatment of Multidrug-Resistant Gram-Negative Nosocomial Infections
Journal of Medicinal Chemistry 2013.0
Structure−Activity Relationships of Polymyxin Antibiotics
Journal of Medicinal Chemistry 2010.0
Structure−Function Studies of Polymyxin B Nonapeptide:  Implications to Sensitization of Gram-Negative Bacteria
Journal of Medicinal Chemistry 2000.0
Synthesis and Bioactivity Investigation of the Individual Components of Cyclic Lipopeptide Antibiotics
Journal of Medicinal Chemistry 2018.0
Combination therapy with polymyxin B and netropsin against clinical isolates of multidrug-resistant Acinetobacter baumannii
Scientific Reports 2016.0
Polymyxin B-inspired non-hemolytic tyrocidine A analogues with significantly enhanced activity against gram-negative bacteria: How cationicity impacts cell specificity and antibacterial mechanism
European Journal of Medicinal Chemistry 2021.0
Total and Semisyntheses of Polymyxin Analogues with 2-Thr or 10-Thr Modifications to Decipher the Structure–Activity Relationship and Improve the Antibacterial Activity
Journal of Medicinal Chemistry 2021.0